Holen Sie sich die Stockscreener-App
45.11
0.98%
-0.71
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6.3%Here's What Happened - MarketBeat
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Barclays PLC Purchases 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Goldman Sachs raises target price for dermatological drug maker MoonLake by 32% - Kursiv Media
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap UpHere's Why - MarketBeat
MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset - MSN
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon - Seeking Alpha
Goldman Sachs Upgrades MoonLake Immunotherapeutics (MLTX) - MSN
This little-known biotech stock is a buy that’s primed to double in price, Goldman says - thepress.net
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to Buy at The Goldman Sachs Group - MarketBeat
MoonLake Immunotherapeutics Sees Stock Target Shifts - TipRanks
How the (MLTX) price action is used to our Advantage - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $81.43 - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
MoonLake Immunotherapeutics initiates three new clinical trials - TipRanks
MLTX Crosses Below Key Moving Average Level - Nasdaq
MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG - Yahoo Finance
MoonLake initiates three new clinical trials and further - GlobeNewswire
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab - Finansavisen
MoonLake Expands Sonelokimab Clinical Program with Three Groundbreaking Trials in Major Diseases - StockTitan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Barclays PLC Acquires 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Raised by State Street Corp - Defense World
State Street Corp Increases Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 5.1%Time to Buy? - MarketBeat
When (MLTX) Moves Investors should Listen - Stock Traders Daily
Moonlake Immunotherapeutics Announces Resignation of Kara Lassen as Board Member, Effective December 31, 2024 - Marketscreener.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 3.2%Here's Why - MarketBeat
MoonLake Immunotherapeutics announces board change, incentive plan - Investing.com
MoonLake Immunotherapeutics Announces Board Changes and Incentives - TipRanks
MoonLake Immunotherapeutics announces board change, incentive plan By Investing.com - Investing.com UK
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.9%Here's What Happened - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate - Simply Wall St
Wellington Management Group LLP Cuts Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Trading (MLTX) With Integrated Risk Controls - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.6%What's Next? - MarketBeat
MoonLake Immunotherapeutics' SWOT analysis: stock outlook amid HS market potential - Investing.com
Clear Street sets $108 target on Moonlake Immunotherapeutics stock By Investing.com - Investing.com UK
Clear Street sets $108 target on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
Erste Asset Management GmbH Invests $741,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
1.07%
8.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):